Form 4: Iteos Therapeutics Executive Yvonne McGrath Acquires Stock Options

Yvonne McGrath, Chief Scientific Officer of Iteos Therapeutics, acquired stock options for 153,600 shares of common stock on March 7, 2024.

Summary

• On March 7, 2024, Yvonne McGrath, the Chief Scientific Officer of Iteos Therapeutics, Inc. acquired stock options.
• The stock options grant the right to buy 153,600 shares of Iteos Therapeutics common stock at an exercise price of $11.58.
• The options vest over four years, with 25% vesting on March 7, 2025, and the remainder vesting in equal monthly installments over the following 36 months, contingent upon continued service to the Issuer.
• The options expire on March 7, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices and aligns management interests with shareholders.

Positives

• The acquisition of stock options by a key executive aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company's long-term success.

Future Outlook

The vesting schedule suggests a commitment to the company's future over the next four years by the Chief Scientific Officer.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key talent and align their interests with those of shareholders. This is a standard incentive package for a Chief Scientific Officer.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron also use stock options to incentivize their executives.
• The vesting schedule and exercise price are generally in line with industry norms for similar roles and company size.

Stakeholder Impact

• Shareholders may view this as a positive sign, aligning management's interests with the company's performance.
• Employees may see this as a standard practice for executive compensation.

Key Dates